Chemoresistance is a major problem in successful cancer therapy. Lysine-specific demethylase 5B (KDM5B), is a member of the KDM5 family of histone demethylases, whose dysregulation has been observed in numerous types of cancer and plays a role in drug tolerance. The present study examined KDM5B expression in high risk neuroblastoma cell lines. Its level was markedly reduced in cisplatin-resistant cells, UKF-NB-4CDDP, compared with parental sensitive cells UKF-NB-4. Moreover, KDM5B-silencing did not affect either viability nor the response to CDDP in resistant cells, and led to increase of proliferation and migration in CDDP resistant cells but not in sensitive ones. Compliant with these results, short interfering KDM5B transfection resulted in increased S phase in resistant cells. Overall, these findings suggested that KDM5B may be involved in the survival mechanisms of neuroblastoma cells, which makes KDM5B a promising factor for the prediction of sensitivity to CDDP that should therefore be considered for future research.

Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University and Motol University Hospital 15006 Prague Czech Republic

Zobrazit více v PubMed

Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27–36. doi: 10.1093/carcin/bgp220. PubMed DOI PMC

Dawson MA, Kouzarides T. Cancer epigenetics: From mechanism to therapy. Cell. 2012;150:12–27. doi: 10.1016/j.cell.2012.06.013. PubMed DOI

Greer EL, Shi Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13:343–357. doi: 10.1038/nrg3173. PubMed DOI PMC

Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M. The role of histone demethylases in cancer therapy. Mol Oncol. 2012;6:683–703. doi: 10.1016/j.molonc.2012.07.004. PubMed DOI PMC

Li X, Su Y, Pan J, Zhou Z, Song B, Xiong E, Chen Z. Connexin 26 is down-regulated by KDM5B in the progression of bladder cancer. Int J Mol Sci. 2013;14:7866–7879. doi: 10.3390/ijms14047866. PubMed DOI PMC

Sun H, Jiang W, Hu J, Ma Z. Prognostic value of elevated KDM5B expression in patients with laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2019;12:3500–3506. PubMed PMC

Bamodu OA, Huang WC, Lee WH, Wu A, Wang LS, Hsiao M, Yeh CT, Chao TY. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer. 2016;16:160. doi: 10.1186/s12885-016-2108-5. PubMed DOI PMC

Plch J, Hrabeta J, Eckschlager T. KDM5 demethylases and their role in cancer cell chemoresistance. Int J Cancer. 2019;144:221–231. doi: 10.1002/ijc.31881. PubMed DOI

Cloos PAC, Christensen J, Agger K, Helin K. Erasing the methyl mark: Histone demethylases at the center of cellular differentiation and disease. Genes Dev. 2008;22:1115–1140. doi: 10.1101/gad.1652908. PubMed DOI PMC

Li G, Kanagasabai T, Lu W, Zou MR, Zhang SM, Celada SI, Izban MG, Liu Q, Lu T, Ballard BR, et al. KDM5B is essential for the hyperactivation of PI3K/AKT signaling in prostate tumorigenesis. Cancer Res. 2020;80:4633–4643. doi: 10.1158/0008-5472.CAN-20-0505. PubMed DOI PMC

Kuo YT, Liu YL, Adebayo BO, Shih PH, Lee WH, Wang LS, Liao YF, Hsu WM, Yeh CT, Lin CM. JARID1B Expression plays a critical role in chemoresistance and stem cell-like phenotype of neuroblastoma cells. PLoS One. 2015;10:e0125343. doi: 10.1371/journal.pone.0125343. PubMed DOI PMC

Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–2211. doi: 10.1056/NEJMra0804577. PubMed DOI PMC

Cheung NK, Dyer MA. Neuroblastoma: Developmental biology, cancer genomics, and immunotherapy. Nat Rev Cancer. 2013;13:397–411. doi: 10.1038/nrc3526. PubMed DOI PMC

Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, Fukuzawa M. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol. 2007;30:1189–1196. PubMed

Brodeur GM, Sawada T, Tsuchida YVP, editors. M. S. MYCN Amplification in Neuroblastoma, corp-author. Neuroblastoma. Elsevier Science B.V; 2000. pp. 75–84.

Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun. 2006;351:192–197. doi: 10.1016/j.bbrc.2006.10.020. PubMed DOI PMC

Maeshima R, Moulding D, Stoker AW, Hart SL. MYCN Silencing by RNAi induces neurogenesis and suppresses proliferation in models of neuroblastoma with resistance to retinoic acid. Nucleic Acid Ther. 2020;30:237–248. doi: 10.1089/nat.2019.0831. PubMed DOI PMC

Bachetti T, Di Paolo D, Di Lascio S, Mirisola V, Brignole C, Bellotti M, Caffa I, Ferraris C, Fiore M, Fornasari D, et al. PHOX2B-mediated regulation of ALK expression: In vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS One. 2010;5:e13108. doi: 10.1371/journal.pone.0013108. PubMed DOI PMC

Di Paolo D, Pastorino F, Brignole C, Corrias MV, Emionite L, Cilli M, Tamma R, Priddy L, Amaro A, Ferrari D, et al. Combined replenishment of miR-34a and let-7b by targeted nanoparticles inhibits tumor growth in neuroblastoma preclinical models. Small. 2020;16:e1906426. doi: 10.1002/smll.201906426. PubMed DOI

Olechnowicz SW, Fedele AO, Peet DJ. Hypoxic Induction of the Regulator of G-protein signalling 4 gene is mediated by the hypoxia-inducible factor pathway. PLoS One. 2012;7:e44564. doi: 10.1371/journal.pone.0044564. PubMed DOI PMC

Zaatiti H, Abdallah J, Nasr Z, Khazen G, Sandler A, Abou-Antoun TJ. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration. Int J Oncol. 2018;52:787–803. PubMed PMC

Cormier N, Yeo A, Fiorentino E, Paxson J. Optimization of the wound scratch assay to detect changes in murine mesenchymal stromal cell migration after damage by soluble cigarette smoke extract. J Vis Exp. 2015:e53414. PubMed PMC

Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:e36. doi: 10.1093/nar/30.9.e36. PubMed DOI PMC

Bedrnicek J, Vicha A, Jarosova M, Holzerova M, Cinatl J, Jr, Michaelis M, Cinatl J, Eckschlager T. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma. 2005;52:415–419. PubMed

Procházka P, Libra A, Zemanová Z, Hřebačková J, Poljaková J, Hraběta J, Bunček M, Stiborová M, Eckschlager T. Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells. Cancer Sci. 2012;103:334–341. doi: 10.1111/j.1349-7006.2011.02137.x. PubMed DOI

Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2011;81:303–311. doi: 10.1111/j.1399-0004.2011.01809.x. PubMed DOI PMC

Pippa S, Mannironi C, Licursi V, Bombardi L, Colotti G, Cundari E, Mollica A, Coluccia A, Naccarato V, La Regina G, et al. Small molecule inhibitors of KDM5 histone demethylases increase the radiosensitivity of breast cancer cells overexpressing JARID1B. Molecules. 2019;24:1739. doi: 10.3390/molecules24091739. PubMed DOI PMC

Xu W, Zhou B, Zhao X, Zhu L, Xu J, Jiang Z, Chen D, Wei Q, Han M, Feng L, et al. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance. Int J Biol Sci. 2018;14:1122–1132. doi: 10.7150/ijbs.25881. PubMed DOI PMC

Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, Ma Y, Yu Y, Lin H, Chen AP, Chen CD. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA. 2007;104:19226–19231. doi: 10.1073/pnas.0700735104. PubMed DOI PMC

Klein BJ, Piao L, Xi Y, Rincon-Arano H, Rothbart SB, Peng D, Wen H, Larson C, Zhang X, Zheng X, et al. The histone-H3K4-specific demethylase KDM5B Binds to its substrate and product through distinct PHD fingers. Cell Rep. 2014;6:325–335. doi: 10.1016/j.celrep.2013.12.021. PubMed DOI PMC

Lu PJ, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, Meier-Ewert S, Jones T, Mitchell M, Pitha-Rowe P, Freemont P, Taylor-Papadimitriou J. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem. 1999;274:15633–15645. doi: 10.1074/jbc.274.22.15633. PubMed DOI

Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P, Zhang Y. PLU-1 Is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 2007;25:801–812. doi: 10.1016/j.molcel.2007.03.001. PubMed DOI

Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue H, et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: Involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer. 2010;9:59. doi: 10.1186/1476-4598-9-59. PubMed DOI PMC

Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25:762–777. doi: 10.1016/j.ccr.2014.04.024. PubMed DOI PMC

Wang L, Mao Y, Du G, He C, Han S. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer. Tumour Biol. 2015;36:2465–2472. doi: 10.1007/s13277-014-2859-z. PubMed DOI PMC

Roesch A, Becker B, Meyer S, Wild P, Hafner C, Landthaler M, Vogt T. Retinoblastoma-binding protein 2-homolog 1: A retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol. 2005;18:1249–1257. doi: 10.1038/modpathol.3800413. PubMed DOI

Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. A Temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583–594. doi: 10.1016/j.cell.2010.04.020. PubMed DOI PMC

Smith V, Foster J. High-risk neuroblastoma treatment review. Children (Basel) 2018;5:114. PubMed PMC

Feriancikova B, Feglarova T, Krskova L, Eckschlager T, Vicha A, Hrabeta J. Miat is an upstream regulator of NMYC and the disruption of the MIAT/NMYC axis induces cell death in NMYC amplified neuroblastoma cell lines. Int J Mol Sci. 2021;22:3393. doi: 10.3390/ijms22073393. PubMed DOI PMC

Zhang L, Sokolowski N, Atmadibrata B, Tao L. Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein. Oncol Rep. 2014;31:1935–1939. doi: 10.3892/or.2014.3006. PubMed DOI

Zhang J, An X, Han Y, Ma R, Yang K, Zhang L, Chi J, Li W, Llobet-Navas D, Xu Y, Jiang Y. Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma. Cell Death Dis. 2016;7:e2358. doi: 10.1038/cddis.2016.262. PubMed DOI PMC

YQ H, Y Z, RJ Z, XD M. Down-regulation of JARID1B expression inhibits cell proliferation, induces apoptosis and blocks cell cycle in human acute lymphoblastic leukemia cells. Eur Rev Med Pharmacol Sci. 2018;22:1366–1373. PubMed

Shigekawa Y, Hayami S, Ueno M, Miyamoto A, Suzaki N, Kawai M, Hirono S, Okada KI, Hamamoto R, Yamaue H. Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma. Oncotarget. 2018;9:34320–34335. doi: 10.18632/oncotarget.26144. PubMed DOI PMC

Yang Z, Xu JX, Fang DP, Ke J. Analysis of key genes reveal lysine demethylase 5B promotes prostate cancer progression. Oncol Lett. 2020;20:62. PubMed PMC